Yotta 2025 Reveals Powerhouse Main Stage Lineup

Digital infrastructure’s most influential voices take the stage at Yotta 2025. With ticket prices increasing on August 2, now’s the time to secure your spot at the industry’s can’t-miss event. NEW YORK, July 28, 2025 /PRNewswire/ — The stage is set. Yotta 2025, the must-attend event for digital infrastructure leaders, has just announced its biggest, boldest […]

SHEIN X TEAMS UP WITH HOUSE OF ONE FOR A CHIC, ACCESSIBLE CAPSULE COLLECTION

The Collection Features Polished Staples, Soft Tailoring, and Affordable Indulgence for Every Moment on Your Calendar LOS ANGELES, July 28, 2025 /PRNewswire/ — SHEIN X, the collaboration platform under global fashion and lifestyle online retailer SHEIN, introduces its latest designer drop: a limited-edition capsule with modern womenswear label House of One. Designed for women who dress […]

AXA XL Appoints Sylvain Bouteillé as Chief Underwriting Officer, Specialty, Americas

NEW YORK , July 28, 2025 /PRNewswire/ — AXA XL is pleased to announce the appointment of Sylvain Bouteillé as Chief Underwriting Officer for Specialty Americas. In this key leadership role, Mr. Bouteillé will oversee the development and execution of AXA XL’s regional strategy for its Specialty insurance division which includes Aviation, Ocean Marine, Political Risk, […]

Sapphire LLC to Launch ReturnMail.ai to Automate Return Mail Processing for High-Volume Organizations

WASHINGTON, July 28, 2025 /PRNewswire/ — Sapphire LLC, founded by entrepreneurs Almustafa “Almo” El Hillo and Deron Cooper, is preparing to launch ReturnMail.ai, a software platform that uses artificial intelligence to automate return mail processing — a longstanding manual workflow in both government and enterprise operations. Continue Reading Launching in August 2025, ReturnMail.ai is conducting demos […]

Avidity Biosciences Announces Completion of Enrollment for HARBOR™, the First Global Phase 3 Trial of Delpacibart Etedesiran (del-desiran) for Treatment of DM1 and Provides Guidance on Regulatory Submission

— Topline data readout from HARBOR study anticipated in Q2 2026 —— Marketing application submissions for del-desiran including in U.S., EU and Japan anticipated to start in H2 2026; on track to potentially be the first globally approved drug for DM1–— On track to share updates from ongoing MARINA-OLE™ trial of del-desiran including long-term 4 mg/kg […]